Impact of the preoperative prognostic nutritional index on postoperative and survival outcomes in colorectal cancer patients who underwent primary tumor resection: a systematic review and meta-analysis

2019 ◽  
Vol 34 (4) ◽  
pp. 681-689 ◽  
Author(s):  
Guangwei Sun ◽  
Yalun Li ◽  
Yangjie Peng ◽  
Dapeng Lu ◽  
Fuqiang Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Meta Analysis ◽  
Tumor Resection ◽  
Prognostic Nutritional Index ◽  
Survival Outcomes ◽  
Nutritional Index ◽  
Colorectal Cancer Patients

Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis

2018 ◽  
Vol 64 ◽  
pp. 30-39 ◽  
Author(s):  
Daniel Boakye ◽  
Bettina Rillmann ◽  
Viola Walter ◽  
Lina Jansen ◽  
Michael Hoffmeister ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Colorectal Cancer Patients

scholarly journals The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Mohammad Hossein Antikchi ◽  
Hossein Neamatzadeh ◽  
Yaser Ghelmani ◽  
Jamal Jafari-Nedooshan ◽  
Seyed Alireza Dastgheib ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Colorectal Cancer Patients

scholarly journals Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

2019 ◽  
Vol 8 (6) ◽  
pp. 3305-3313 ◽  
Author(s):  
Yue Li ◽  
Xingkang He ◽  
Yu’e Ding ◽  
Hongyang Chen ◽  
Leimin Sun
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Colorectal Cancer Patients

scholarly journals Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis

2019 ◽  
Vol 9 (3) ◽  
pp. 1044-1057 ◽  
Author(s):  
Lauren C. Bylsma ◽  
Christina Gillezeau ◽  
Tamer A. Garawin ◽  
Michael A. Kelsh ◽  
Jon P. Fryzek ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Braf Mutations ◽  
Colorectal Cancer Patients

scholarly journals Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Dedong Cao ◽  
Yongfa Zheng ◽  
Huilin Xu ◽  
Wei Ge ◽  
Ximing Xu
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Primary Tumor ◽  
Meta Analysis ◽  
Tumor Resection ◽  
Progression Free Survival ◽  
Primary Tumor Resection ◽  
Cochrane Library ◽  
Colorectal Cancer Patients ◽  
Resected Primary Tumor

AbstractIt is not well determined whether primary tumor resection is associated with better outcomes in metastatic colorectal cancer (mCRC) patients treated with bevacizumab. In this meta-analysis, we aimed to assess the prognostic role of primary tumor resection in mCRC treated with bevacizumab. Electronic databases including the Cochrane library, Embase, and Pubmed were searched until April 2018. Clinical studies assessing the influence of primary tumor resection on the efficacy of bevacizumab in patients with mCRC were identified. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Seven studies including 2760 mCRC patients were finally included. The results of the meta-analysis were in favor of bevacizumab to patients with resected primary tumor in terms of OS (HR = 0.50, 95%CI: 0.39–0.64; p < 0.01), and PFS (HR = 0.65, 95%CI: 0.51–0.81; p < 0.01). Administration of bevacizumab in mCRC patients with resected primary tumor had a better OS (HR = 0.65, 95%CI: 0.56–0.74; p < 0.01), when compared to chemotherapy(CT). Adding bevacizumab to mCRC patients without resection of primary tumor also had a better OS (HR = 0.78, 95%CI: 0.65–0.94; p < 0.01) and PFS (HR = 0.71, 95%CI: 0.57–0.88; p < 0.01) compared to chemotherapy alone. In conclusion, mCRC patients with resected primary tumor have better survival than those without surgery of primary tumor when treated with bevacizumab. Primary tumor resection status should be taken into consideration when using bevacizumab in mCRC.

Sign in / Sign up

Export Citation Format

Share Document